The pig as a pre-clinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms - a PEARRL review

Loading...
Thumbnail Image
Date
2018-04-10
Authors
Henze, Laura J.
Koehl, Niklas J.
O'Shea, Joseph P.
Kostewicz Edmund
Holm, René
Griffin, Brendan T.
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Published Version
Research Projects
Organizational Units
Journal Issue
Abstract
Objectives: In pharmaceutical drug development, preclinical tests in animal models are essential to demonstrate whether the new drug is orally bioavailable and to gain a first insight into in vivo pharmacokinetic parameters that can subsequently be used to predict human values. Despite significant advances in the development of bio‐predictive in vitro models and increasing ethical expectations for reducing the number of animals used for research purposes, there is still a need for appropriately selected pre‐clinical in vivo testing to provide guidance on the decision to progress to testing in humans. The selection of the appropriate animal models is essential both to maximise the learning that can be obtained from such experiments and to avoid unnecessary testing in a range of species. Key findings: The present review, provides an insight into the suitability of the pig model for predicting oral bioavailability in humans, by comparing the conditions in the GIT. It also contains a comparison between the bioavailability of compounds dosed to both humans and pigs, to provide an insight into the relative correlation and examples on why a lack of correlation may be observed. Summary: While there is a general trend towards predicting human bioavailability from pig data, there is considerable variability in the data set, most likely reflecting species specific differences in individual drug metabolism. Nonetheless, the correlation between pigs vs. humans was comparable to that reported for dogs vs. humans. The presented data demonstrate the suitability of the pig as a preclinical model to predict bioavailability in human.
Description
Keywords
Minipigs , Oral drug absorption , Physiologically based pharmacokinetic , Pigs , Preclinical animal model , PBPK
Citation
Henze, L. J., Koehl, N. J., O'Shea, J. P., Kostewicz, E. S., Holm, R. and Griffin, B. T. (2018) 'The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review', Journal of Pharmacy and Pharmacology, 71 (4), pp. 581-602 doi:10.1111/jphp.12912
Copyright
© 2018 Royal Pharmaceutical Society. This is the peer reviewed version of the following article: (2018), The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review. J Pharm Pharmacol., which has been published in final form at https://doi.org/10.1111/jphp.12912. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.